Russian Heart Failure Journal 2008year Place of levosimendan in the treatment of acute heart failure

To access this material please log in or register

Register Authorize

Place of levosimendan in the treatment of acute heart failure

Tereshchenko O. I., Kositsyna I. V., Golubev A. V., Uskach T. M.



Levosimendan presently takes an important place among drugs for inotropic support in therapy of patients with decompensated HF. Although advantage of the drug over the standard medication dobutamine generally has not been confirmed, their efficacy and incidence of side effects are comparable. At the same time an undoubted benefit of levosimendan is its effect on the neuro-humoral profile of patients.
    1.    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353 (9146):9–13.
    2.    Flather M, Yusuf S, Kober L et al. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355 (9215):1575–1581.
    3.    MERIT-HF Study Group. Effect of metoprolol CR / XL in chronic heart failure. Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
    4.    Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
    5.    Моисеев В. С. Острая сердечная недостаточность. Новые возможности лечения с применением сенситизатора кальция левосимендана. Фарма Пресс, 2004.
    6.    Cotter G, Moshkovitz Y, Milovanov O et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4 (3):227–234.
    7.    Nieminen MS, Böhm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (4):384–416.
    8.    Sonnenblick E, Sonnenblick M, Abraham AS. Digoxin treatment and control in the elderly. Isr J Med Sci. 1985;21 (3):276–278.
    9.    Sonnenblick M, Abraham AS, Meshulam Z, Eylath U. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH Br Med J (Clin Res Ed). 1983;286 (6371):1089–1091.
    10.    Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. 1991;325 (21):1468–1475.
    11.    Haikala H, Nissinen E, Etemadzadeh E et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25 (5):794–801.
    12.    Hasenfuss G, Pieske B, Castell M et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98 (20):2141–2147.
    13.    Lancaster MK, Cook SJ. The effects of [Ca2+]i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol. 1997;339 (1):97–100.
    14.    Lilleberg J, Nieminen MS, Akkila J et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19 (4):660–668.
    15.    Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994;81 (4):974–987.
    16.    Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43 (12):2177–2182.
    17.    Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37 (4):367–374.
    18.    Sundberg S, Lilleberg J, Nieminen MS et al. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensi¬tizer, at rest and during exercise in healthy men. Am J Cardiol. 1995;75 (15):1061–1066.
    19.    Nieminen M, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36 (6):1903–1912.
    20.    Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102 (18):2222–2227.
    21.    Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999;288 (1):316–325.
    22.    Kaheinen P, Haikala H. Levosimendan and milrinone increase diastolic coronary flow through opening of the ATP-sensitive potassium channels by different mechanism of action. J Am Call Cardiol. 1998;31 (Suppl C):31С.
    23.    Pataricza J, Hohn J, Petri A et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52 (2):213–217.
    24.    Ukkonen H, Saraste M, Akkila J et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68 (5):522–531.
    25.    Edes I, Kiss E, Kitada Y et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77 (1):107–113.
    26.    Sato S, Talukder MAH, Sugawara H et al. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1‑loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol. 1998;30 (6):1115–1128.
    27.    Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther. 1997;283 (1):375–383.
    28.    Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol. 1995;26 (Suppl 1): S63–69.
    29.    Nieminen MS, Sandell E-P, Vuorinen J, Lehtonen L. A multicenter dose-finding study on the effects of continuous infusion of levosimendan on cardiac output in patients with congestive heart failure. Internal report: Orion Pharma; 1998 October 26. Report No.: 300105.
    30.    Nieminen MS., Lilleberg J, Sundberg S et al. Dose response study of acute i. v. levosimendan in healthy volunteers. Internal report: Orion Pharmaceutica; 1993 February. Report No.: 300101.
    31.    Antila S, Kivikko M. Pharmacokinetics of levosimendan and its metabolites during and after a one week continuous infusion of levosimendan to patients with heart failure. Groups 1 and 2. Internal report: Orion Pharma; 2000. Report No.: 3001058.
    32.    Pentikainen P, Antila S, Hayaha M et al. Pharmacokinetics of levosimendan in healthy volunteers and in patients with stable congestive heart failure. Internal report: Orion Pharmaceutica; 1994 February. Report No.: 300103.
    33.    Wikberg T. Profile of urinary metabolites of levosimendan in man. Internal report: Orion Pharma; 1994 November 1. Report No.: CR94031200206.
    34.    Wikberg T. Biotransformation of (±)-OR-1259 in man – chromatographic characterisation of the urinary metabolites. Internal report: Orion Pharma; 1992 March 12. Report No.: CR92032000053.
    35.    Karlsson M., Wikberg T. Determination of levosimendan in human urine with high-performance liquid-chromatography and UV-detection – study no. 3001007. Internal report: Orion-Farmos Pharmaceuticals; 1994 January 11. Report No.: CR93031200142.
    36.    Karlsson M., Wikberg Т. Determination of levosimendan in human plasma by non-enantioselective and enantioselective high performance liquid chromatography with UV-detection – study No. 3001011. Internal report: Orion-Farmos Pharmaceuticals; 1992 December 14. Report No.: CR92032000089.
    37.    Sandell E-P, Aalto T, Antila S et al. The effects of severe congestive heart failure on the pharmacokinetics of levosimendan. Eur J Clin Pharmacol. 1997;52 (Suppl):55.
    38.    Kivikko M, Antila S, Eha J et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42 (1):43–51.
    39.    Karlsson M, Jonsson N, McFadyen L. A population pharmacokinetic analysis of levosimendan and its metabolites (OR1855 and OR1896). Research report: Uppssala University; 1998 January 30. Report No.: 3001059.
    40.    Jonsson EN, Antila S, McFadyen L et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003;55 (6):544–551.
    41.    Moiseyev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432.
    42.    Omerovic E, Ramunddal T, Albertsson P, Matejka G. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock. Eur J Heart Fail. Supplements. 2007;6 (1):107.
    43.    Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360 (9328):196–202.
    44.    Peck P. Levosimendan Shows Significant Survival Benefit in Decompensated Heart Failure. ACC 53rd Annual Scientific Session: Abstract 835–6. Presented March 9, 2004.
    45.    Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure. The SURVIVE Randomized Trial. JAMA. 2007;297 (17):1883–1891.
    46.    Teerlink JR, Delgado-Herrera L, Thakkar R et al. Clinical composite endpoint classification of REVIVE II corresponds to all-cause mortality risk. Eur J Heart Fail. Supplements. 2007;6 (1):106.
    47.    Kitsiou AN, Kelepouris P, Anadiotis A, Karas S. Extent of myocardial scar: Does it affect improvement of neurohormonal activation after levosimendan infusion? Eur J Heart Fail. Supplements. 2007;6 (1):13.
    48.    Cavusoglu Y, Tek M, Birdane A et al. Comparison of levosimendan and dobutamine treatment in reducing N terminal pro-brain natriuretic peptide levels in patients with acutely decompensated heart failure. Eur J Heart Fail. Supplements. 2007;6 (1):97.

To access this material please log in or register

Register Authorize
Ru En